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BACKGROUND
Five-year childhood cancer survival rates
have increased to 80–90% for some
tumours due to intensified treatments
and better supportive care imposed on an
incidence stable over four decades.1 2
Between 2005 and 2012, the number of
UK survivors has risen from 26 000 to
33 000, or from 1:1000 to 1:715 UK
adults.3 4 However, 40% experience
chronic severe or life-threatening conse-
quences (‘late effects’) of their tumour
and/or its treatment.5 The recent
National Cancer Survivorship Initiative
(NCSI) has highlighted the unmet need
in service provision for adult childhood
cancer survivors, with a proposed sur-
vivorship framework and stratified care
pathways modelled on >20 years’ prior
experience.6 7
In March 2013, the Scottish
Intercollegiate Guidelines Network
(SIGN) published updated guidance on
long-term follow-up of childhood cancer
survivors to aid the ‘identification, assess-
ment and management of late effects’
aimed at primary, secondary and tertiary
healthcare practitioners.8 The Guideline
Development Group (GDG) included
representatives from paediatric haematol-
ogy, oncology, endocrinology, reproduct-
ive medicine, cardiology, general
paediatrics and general practice, as well
as a survivor.
PREVIOUS AND OTHER ASSOCIATED
GUIDELINES
The previous SIGN 76 guideline was
published in 2004. This revision updates
information on fertility preservation,
cardiac late effects and patient informa-
tion provision, and provides new sections
on subsequent primary cancers (SPCs),
bone health and metabolic syndrome.
The UK Children’s Cancer Study Group’s
(UK CCSG) best practice statement9 is a
potentially valuable companion guideline
for tertiary care practitioners requiring
details of therapeutic regimens and their
toxicity profiles to individualise care for
those most affected.
KEY ISSUES
▸ Section 11: long-term follow-up provides a
useful summary of the recommendations.
It recognises the multisystemic and evolv-
ing nature of late effects over decades of
survival, concluding a need for lifelong
multidisciplinary follow-up (table 1). The
authors suggest a three-tiered follow-up
stratified by disease-related and/or
treatment-related morbidity risk (table 2)
and list the key multidisciplinary profes-
sionals required (box 1).
▸ Subsequent primary cancers (SPCs)—The
British Childhood Cancer Survivor
Study10 and others have shown an excess
SPC risk—>50% due to gastrointestinal,
genitourinary, breast and lung cancers—
persisting into old age.
▸ Fertility—The impact of cancer treatment
on the pituitary–gonadal axis, reproductive
capacity and options for pretreatment fer-
tility preservation are complex and differ
between the sexes (see British Fertility
Society review for a fuller discussion11). In
boys, post-treatment sub/infertility may
exist despite a normal puberty and
potency.12 With intracytoplasmic sperm
injection, oligospermia is no barrier to fer-
tility preservation, while long-term sper-
matogenic recovery is possible.13 By
contrast, pubertal delay or secondary
amenorrhoea may herald sub/infertility in girls
whose options are more limited. Pretreatment
gonadotropin-releasing hormone analogues,
ovarian transposition and oocyte collection
are unproven and/or impracticable.
Prepubertal children of either sex have no
recommended options outside a clinical
trial. Miscarriage rates are increased, but
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Table 1 Summary of SIGN recommendations on long-term follow-up of survivors of childhood cancer
Late effect High-risk factors Specific late effects Screening methods/ management
Evidence
level/grade
Subsequent primary
cancers (SPCs)
Genetic predisposition, eg, NF-1 Dependent on syndrome As per guidance for specific syndromes
Radiotherapy Delayed presentation >5 years from treatment, at
edge of radiation field (eg, mediastinal radiotherapy
and breast SPCs)
No consensus
Promote healthy lifestyle behaviours
3/C
Chemotherapy* (alkylating agents,
epipodophyllotoxins)
Increased risk of all SPCs No consensus
Promote healthy lifestyle behaviours
3/C
Sub-/infertility Both sexes
Cranial radiotherapy Hypogonadotropic hypogonadism (pubertal
arrest/ delay)
See individual sections for assessment depending on sex 3
Pelvic radiotherapy Sexual dysfunction Consider psychological referral 3–4/D
Boys
Chemotherapy* (alkylating agents) Azoospermia Semen analysis±cryopreservation, FSH, inhibin B 3/D
Gonadal radiotherapy/ total body
irradiation (TBI)
Azoospermia
Hypergonadotropic hypogonadism (less likely—
pubertal arrest/ delay, sexual dysfunction)
Semen analysis±cryopreservation, FSH, inhibin B
Regular pubertal assessment, LH, testosterone
±pubertal induction/ testosterone supplementation
2±3/D
Girls
Chemotherapy* (alkylating agents) Hypergonadotropic hypogonadism (pubertal arrest/
delay/ oligoamenorrhoea)
Regular pubertal assessment, FSH, AMH
±pubertal induction/ female hormone replacement therapy
±oocyte cryopreservation if postpubertal
3/D
Abdominopelvic radiotherapy Hypergonadotropic hypogonadism
Uterine dysfunction (premature delivery, low birth
weight)
Cardiac effects Chemotherapy (anthracyclines) Congestive heart failure Echocardiography: Fractional shortening (FS) and ejection fraction (EF)
measurements
2–3 yearly if anthracycline dose >250 mg/m2
5 yearly if anthracycline dose <250 mg/m2
Treat as per regular heart failure/cardiovascular disease guidelines
Promote healthy lifestyle behaviours
3–4/D
3/D
Cardiac/mediastinal radiotherapy Cardiovascular (especially coronary artery) disease
Bone health Chemotherapy (glucocorticoids, high dose
methotrexate, 6-mercaptopurine)
Cranial radiotherapy
Bone marrow transplantation
Endocrine dysfunction (GH deficiency,
hypogonadism, hypothyroidism)
Osteoporosis (osteonecrosis with glucocorticoids) Dual energy X-ray absorptiometry (DXA)/ peripheral quantitative CT/ quantitative
ultrasound: BMD or bone mineral content (BMC) Z-scores adjusted for age, sex
and height 2 years post-end of treatment
Serial measurements not required unless abnormal or clinical change
Sex steroid replacement
Promote healthy lifestyle behaviours
3/D
Metabolic
syndrome
ALL (especially after bone marrow
transplantation)
Brain tumours (especially after cranial
radiotherapy and growth hormone
deficiency)
Obesity
Dyslipidaemia
Insulin resistance
Cardiovascular disease
BP and BMI: Annually in all survivors
Fasting glucose, insulin, lipid profile:
2-yearly if obese/ overweight
5-yearly if normal weight
Treat as per regular obesity guidelines
3–4/D
Cognitive outcomes Cranial radiotherapy Cognitive decline
Psychosocial dysfunction
Neuropsychological assessment: Pretreatment and then annually 3/D
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there is no excess of congenital or genetic disorders in
offspring.
▸ Cardiac effects—Anthracycline-induced heart failure and
mediastinal irradiation-induced cardiovascular disease
may take years to manifest and may be additive. There is
limited evidence for prophylactic ACE inhibitors or
β-blockers, hence standard heart failure management is
recommended.
▸ Bone health—Bone mineral density (BMD) as measured
by DEXA is age-dependent, sex-dependent, puberty-
dependent and height-dependent, thus Z-scores rather
than T-scores need cautious interpretation. The only
evidence-based treatment for osteopenia is sex steroid
replacement, although its effect on fracture risk is
unknown.
▸ Metabolic syndrome—Studies are limited to acute lympho-
blastic leukaemia (ALL) and brain tumour survivors. A
normal body mass index (BMI) does not preclude insulin
resistance and dyslipidaemia.14 Annual blood pressure and
BMI assessments are recommended.
▸ Cognitive/ psychosocial issues—Cranial irradiation-induced
cognitive decline is age-dependent, sex-dependent and
dose-dependent and compounded by adjuvant chemother-
apy.15 All survivors are at increased risk of psychosocial
maladjustment and warrant consideration for extra educa-
tional support.
▸ Growth—All new cancer patients require accurate auxol-
ogy at diagnosis and regularly thereafter to adult height,
although the feasibility of performing this means that
low-risk patients will need monitoring in primary or sec-
ondary care. Growth velocity requires interpreting in
light of puberty and hormone replacement. Growth
hormone (GH) replacement—important for bone min-
eralisation and childhood growth—does not increase
cancer recurrence and should be substituted early par-
ticularly after spinal irradiation as it cannot fully reverse
the detriment on adult height.16 17
▸ Thyroid dysfunction—Low-dose irradiation scatter can
cause compensated and frank primary hypothyroidism
years after treatment. Secondary hypothyroidism
(thyroid-stimulating hormone deficiency) attributed to
cranial irradiation is, in our experience, unusual outside
the context of suprasellar tumours. Lifelong monitoring
is recommended alongside education on
self-examination.
▸ Information provision—Information on healthy lifestyle,
support networks and the importance of long-term
follow-up should be given to all survivors.
UNDERLYING EVIDENCE BASE
These SIGN guidelines represent a synthesis of sys-
tematic reviews summarising the best available evi-
dence in accordance with standardised
methodology.18 Unlike the National Institute for
Health and Care Excellence (NICE), SIGN does not
require a mandatory cost-effectiveness analysis.
Recommendations graded A–D are based on aTa
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hierarchy of evidence from level 1 (meta-analyses, sys-
tematic reviews or randomised controlled trials) to
level 4 (expert opinion).
HOW DO I IMPLEMENT THESE GUIDELINES IN MY
PRACTICE?
▸ Primary care practitioners need to be alert to the many
late organ toxicities incurred by increasing treatment
intensity that may manifest decades after treatment.
Lifelong surveillance for endocrinopathies, subfertility,
SPCs, cardiovascular disease, obesity and metabolic syn-
drome particularly in low-risk patients can only realistic-
ally occur in primary care, alongside supporting healthy
lifestyle behaviours (including monitoring vitamin D
status) and participation in secondary/tertiary follow-up.
Young adult survivors may seek support for psycho-
logical illness or subfertility.
▸ Secondary care practitioners will monitor growth,
puberty, thyroid function and neurocognitive develop-
ment until adulthood, with appropriate specialist refer-
ral. Letters of support may be required for missed school
attendances, statementing and disability living allowance
applications. Adult physicians will be responsible for life-
long monitoring of cardiovascular disease, obesity,
thyroid function, bone and sexual health, fertility and
SPCs.
▸ Tertiary care practitioners should see all those at highest
risk (brain, pelvic, bone tumour and transplant survivors)
for hypothalamopituitary hormone dysfunction, fertility
counselling, cardiac and cognitive assessments and psy-
chological support. Clear end-of-treatment summaries
with information regarding long-term surveillance needs
and likely consequences are required. Implicit in the
latter are the increased resources needed for such
age-appropriate tertiary assessment and rehabilitation
services.
CONTROVERSIES AND UNADDRESSED ISSUES
The level of care provided to childhood cancer survi-
vors remains highly variable across the UK,19 and con-
trolled trials on the optimum frequency, duration and
Table 2 Suggested risk stratification of levels of follow-up for
5-year childhood cancer survivors after completion of treatment
(reproduced from SIGN 132: Long term follow up of survivors of
childhood cancer by kind permission)8
Level Treatment Follow-up Frequency Examples
1 Surgery alone
Low-risk
chemotherapy
Postal/
telephone
1–2 yearly Survivors of
Wilms’ tumour
stage
I/II Langerhans cell
histiocytosis (single
system disease)
Germ cell tumours
(surgery only)
2 Chemotherapy
Cranial
radiotherapy
≤24 Gy
Nurse/
primary
care-led
1–2 yearly Majority of
survivors
3 Any other
radiotherapy
(cranial
radiotherapy
>24 Gy)
Megatherapy
(ie, high-dose
chemotherapy)
Medically
supervised
dedicated
long-term
follow-up
clinic
Annually Survivors of
Any brain tumour
Bone marrow
transplantation
Stage 4 patients of
any tumour type
SIGN, Scottish Intercollegiate Guidelines Network.
Box 1 Suggested members of the multidisciplinary
follow-up team (with one member nominated as the
key worker) (reproduced by kind permission from
Scottish Intercollegiate Guidelines Network (SIGN)
132: Long term follow up of survivors of childhood
cancer)8
▸ Adult oncologist
▸ Paediatric oncologist
▸ Radiation oncologist
▸ Paediatric neurosurgery
▸ Paediatric endocrinologist
▸ Paediatric neurologist
▸ Specialist nurse/nurse practitioner
▸ Clinical psychologist
▸ General practitioner
▸ Dentist
▸ Optician
▸ Social worker
Clinical bottom line
▸ Childhood cancer survivors require lifelong monitor-
ing to limit late consequences of their tumour and/or
treatment, but the optimum service delivery model
remains incompletely defined.
▸ While risk factors associated with certain late effects
are known, many evolve over decades, with data
interpretation confounded by retrospective and cross-
sectional study designs.
▸ Tertiary centres are developing one-stop
age-appropriate multidisciplinary services for those at
highest risk, but the majority will remain in primary
and secondary care.
▸ All practitioners must thus be aware of consequences
of cancer cure and thresholds for referral. In this
respect, the SIGN guidance provides a helpful way
forward for much needed service development and
summarises the current evidence base.
▸ More prospective long-term morbidity outcome
studies are required from current interventional trials
to define the balance between improving survival
with increasing treatment intensity and the quality of
survivorship.
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quality of follow-up are still needed to determine the
effectiveness of secondary prevention of, for example,
congestive cardiac failure or hypocortisolaemic
(Addisonian) crises. A pan-European prospective
cohort study of ∼80 000 childhood cancer survivors
(PanCareSurFup) is currently examining risk factors
for cardiac disease, SPCs and late mortality.20 Several
issues not discussed in the guideline are summarised
in box 2.
FURTHER RESOURCES
▸ Scottish Intercollegiate Guidelines Network (SIGN) 132:
Long-term follow-up of survivors of childhood cancer
http://www.sign.ac.uk/pdf/sign132.pdf
▸ UK Children’s Cancer Study Group (UKCCSG) Best
Practice Statement: Therapy-Based Long-Term Follow-Up
(2nd ed.) http://www.cclg.org.uk/dynamic_files/LTFU-full.
pdf
▸ National Cancer Survivorship Initiative (NCSI) website
http://www.ncsi.org.uk/
▸ Pan-European Network for Care of Survivors after
Childhood and Adolescent Cancer (PanCare) http://www.
pancare.eu/en/
▸ British Fertility Society (BFS) Consultation Paper on Fertility
in Childhood Cancer http://www.britishfertilitysociety.org.uk/
practicepolicy/documents/fccpaper.pdf
Acknowledgements We would like to thank SIGN for their
kind permission in the use of table 2 and box 1 for this review.
Contributors H-WG wrote the initial manuscript draft, and
HAS provided significant editions and useful expert opinion.
Competing interests None.
Provenance and peer review Commissioned; externally peer
reviewed.
Open Access This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 3.0) license, which permits others to
distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different
terms, provided the original work is properly cited and the use
is non-commercial. See: http://creativecommons.org/licenses/by-
nc/3.0/
REFERENCES
1 Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer
survival trends in Europe: a EUROCARE Working Group
study. J Clin Oncol 2005;23:3742–51.
2 Office for National Statistics. Cancer statistics registrations:
registrations of cancer diagnosed in 2009, England (MB1 40).
London: Office for National Statistics, 2011.
3 Stiller CA. Childhood cancer in Britain: incidence, survival,
mortality. Oxford: Oxford University Press, 2007.
4 Skinner R, Wallace WH, Levitt G. Long-term follow-up of
children treated for cancer: why is it necessary, by whom,
where and how? Arch Dis Child 2007;92:257–60.
5 Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health
conditions in adult survivors of childhood cancer. N Engl J
Med 2006;355:1572–82.
6 Department of Health, Macmillan Cancer Support, NHS
Improvement. Living with and beyond cancer: taking action to
improve outcomes. London: National Cancer Survivorship
Initiative (NCSI), Department of Health, 2013.
7 Wallace WH, Blacklay A, Eiser C, et al. Developing strategies
for long term follow up of survivors of childhood cancer. BMJ
2001;323:271–4.
Box 2 Critical review
▸ Timely update limited by absence of high-quality evi-
dence for the cost effectiveness of the recommended
lifelong three-tiered follow-up framework. Evidence
graded mainly C–D (none above B) consisting largely
of uncontrolled qualitative studies of patient/family
satisfaction, not morbidity or mortality.21
▸ Inherent bias in Guideline Development Group (GDG)
composition—no renal, respiratory or neurology/
neuropsychology representatives with consequent
omissions of important treatment-related renal,
neurological and pulmonary toxicities (detailed in the
UK CCSG Best Practice Statement).
▸ The Human Fertilisation and Embryology Act
(2008)22 governing storage and use of haploid
gametes and embryos is not mentioned. It mandates
personal (not proxy) consent, even in children; hence
an intellectual (‘Gillick’) competency assessment is
required. Blood-borne virus (HIV, hepatitis B & C)
testing prior to storage and written consent regarding
use after death is also necessary.
▸ The endocrine and cognitive outcomes sections have
not been updated (cited references are over 15 years
old). As a result:
– The cited data on pituitary craniopharyngiomas
and hypothalamic obesity have been superseded
by prospective outcome studies,23 retrospective
reviews24 and guidelines,25 not identified by the
GDG search strategy.
– The recommendation that all cranially irradiated
patients receive annual cognitive assessments has
never been achieved even in the context of a pro-
spective trial.15
– The perception that cranial irradiation per se
causes eventual life-threatening pituitary deficits
(eg, adrenocorticotropic hormone deficiency defi-
ciency) persists from 1987 data on adult pituitary
tumours; newer evidence suggests pituitary dys-
function is confined to GH deficiency and preco-
cious puberty except in the presence of a
suprasellar tumour, which is most likely
causative.26
– Given the risk of radiation-associated subsequent
primary cancers (1% lifetime risk of thyroid
cancer), the carcinogenicity of nuclear fallouts
and an elevated thyroid-stimulating hormone
(TSH)27 and the long-term cardiovascular mortal-
ity risk of subclinical hypothyroidism,28 few clini-
cians would overlook screening for and treating
compensated hypothyroidism (raised TSH, normal
free T4) after neck irradiation.
Guideline review
142 Gan H-W, et al. Arch Dis Child Educ Pract Ed 2014;99:138–143. doi:10.1136/archdischild-2013-305452
8 Scottish Intercollegiate Guidelines Network (SIGN). Long term
follow up of survivors of childhood cancer. Edinburgh: SIGN,
2013. (SIGN publication no. 132).
9 Skinner R, Wallace WHB, Levitt GA. eds. Therapy based
long-term follow-up. 2nd edn. UK Children’s Cancer Study
Group (UK CCSG) Late Effects Group, 2005.
10 Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of
subsequent primary neoplasms among survivors of childhood
cancer. JAMA 2011;305:2311–19.
11 Multidi sciplinary Working Party convened by the British
Fertility Society. A strategy for fertility services for survivors of
childhood cancer. Hum Fertil (Camb) 2003;6:A1–A39.
12 Gan HW, Spoudeas HA. Preserving reproductive capacity in
young boys with cancer. Trends Urol Men’s Health
2013;4:8–12.
13 Bahadur G, Ozturk O, Muneer A, et al. Semen quality before
and after gonadotoxic treatment. Hum Reprod 2005;20:774–81.
14 Steffens M, Beauloye V, Brichard B, et al. Endocrine and
metabolic disorders in young adult survivors of childhood
acute lymphoblastic leukaemia (ALL) or non-Hodgkin
lymphoma (NHL). Clin Endocrinol (Oxf) 2008;69:819–27.
15 Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of
health status 7 years after addition of chemotherapy to
craniospinal irradiation for medulloblastoma: a follow-up study
in PNET 3 trial survivors on behalf of the CCLG (formerly
UKCCSG). J Clin Oncol 2007;25:4239–45.
16 Kennedy C, Bull K, Chevignard M, et al. Quality of Survival
and Growth in Children and Young Adults in the PNET4
European Controlled Trial of Hyperfractionated Versus
Conventional Radiation Therapy for Standard-Risk
Medulloblastoma. Int J Radiat Oncol Biol Phys 2014;88:
292–300.
17 Sklar CA, Mertens AC, Mitby P, et al. Risk of disease
recurrence and second neoplasms in survivors of childhood
cancer treated with growth hormone: a report from the
Childhood Cancer Survivor Study. J Clin Endocrinol Metab
2002;87:3136–41.
18 Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50:
A guideline developer’s handbook. Edinburgh: SIGN, 2011.
19 Taylor A, Hawkins M, Griffiths A, et al. Long-term follow-up
of survivors of childhood cancer in the UK. Pediatr Blood
Cancer 2004;42:161–8.
20 Hjorth L, Kvarnstrom E. Pancare Childhood and Adolescent
Cancer Survivor Care and Follow-up Studies. 2013. [cited
2013 2 December 2013]; http://www.pancaresurfup.eu
21 Heirs M, Suekarran S, Slack R, et al. A systematic review
of models of care for the follow-up of childhood cancer
survivors. Pediatr Blood Cancer 2013;60:351–6.
22 Human Fertilisation and Embryology Act 1990 (modified
2008). London, UK: HMSO, 2008.
23 Muller HL, Gebhardt U, Teske C, et al. Post-operative
hypothalamic lesions and obesity in childhood
craniopharyngioma: results of the multinational prospective
trial KRANIOPHARYNGEOM 2000 after 3-year follow-up.
Eur J Endocrinol 2011;165:17–24.
24 Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas
in children and adults: systematic analysis of 121 cases with
long-term follow-up. Clin Endocrinol (Oxf) 2005;62:397–409.
25 Spoudeas HA, Albanese A, Saran F, et al. Chapter One—
Craniopharyngioma. In: Spoudeas HA, Harrison B. eds.
Paediatric endocrine tumours: a multidisciplinary consensus
statement of best practice from a working group convened
under the auspices of the British Society for Paediatric
Endocrinology & Diabetes (BSPED) and United Kingdom
Children’s Cancer Study Group (UKCCSG) (rare tumour
working groups). 1st edn. Crawley, UK: Novo Nordisk Ltd.,
2005:16–46.
26 Darzy KH, Shalet SM. Hypopituitarism following radiotherapy.
Pituitary 2009;12:40–50.
27 Jereczek-Fossa BA, Alterio D, Jassem J, et al. Radiotherapy-induced
thyroid disorders. Cancer Treat Rev 2004;30:369–84.
28 Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical
hypothyroidism and the risk of coronary heart disease and
mortality. JAMA 2010;304:1365–74.
Guideline review
Gan H-W, et al. Arch Dis Child Educ Pract Ed 2014;99:138–143. doi:10.1136/archdischild-2013-305452 143
